{"id":"89zr-dfo-girentuximab","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"25%","effect":"Nausea"},{"rate":"20%","effect":"Diarrhea"}]},"status":"active","trials":["NCT07179770"],"aliases":["TLX250-CDx"],"patents":[],"pricing":[],"timeline":[],"aiSummary":"Targeting CD22 Used for Relapsed or refractory CD22-positive B-cell non-Hodgkin lymphoma.","brandName":"89Zr-DFO-girentuximab","companyId":"nyu-langone-health","mechanism":{"_ai_source":"groq-llama-8b","explanation":"89Zr-DFO-girentuximab is a radioligand that targets CD22, a transmembrane sialic acid-binding immunoglobulin-type lectin, which is expressed on the surface of B cells.","oneSentence":"Targeting CD22","_ai_confidence":"high"},"commercial":null,"companyName":"NYU Langone Health","competitors":[],"genericName":"89Zr-DFO-girentuximab","indications":{"approved":[{"name":"Relapsed or refractory CD22-positive B-cell non-Hodgkin lymphoma"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}